# Cyto-KIK (NCT04322955)

> CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

No report yet. It can be ordered.

- Drugs tested: cabozantinib plus nivolumab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04322955
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Mark Stein
- Conditions: Kidney Cancer; Renal Cell Carcinoma
- Interventions: Cabozantinib; Nivolumab; Cytoreductive nephrectomy
- Enrollment: 38
- Primary outcome: Percentage of Participants with a Complete Response

## Indexed commentary on Cyto-KIK so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 3 YouTube videos
- 2 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cyto-kik-nct04322955

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04322955", "email": "<work email>"}; the inbox owner confirms by the emailed link.